Etiome Appoints Jean Lachowicz as Chief Scientific Officer to Drive Drug Development Forward

Etiome Welcomes Jean Lachowicz as Chief Scientific Officer

Etiome, a pioneering company reshaping the detection and preemption of disease progression, has recently announced the appointment of Jean Lachowicz, Ph.D., MBA, as the new Chief Scientific Officer. This strategic move is set to enhance the company's innovative Temporal Biodynamics™ platform and accelerate the journey of drug discovery and development toward clinical application, ultimately aiming to deliver Biostaged Medicines that offer improved health outcomes for individuals at risk of chronic or progressive diseases.

Dr. Lachowicz brings with her an impressive three-decade-long career in drug discovery and development across various disease areas, including neurology, oncology, immunology, rare diseases, and cardiometabolic disorders. Before joining Etiome, she served as the Senior Vice President and Chief Development Scientist at Schrodinger, focusing on asset strategy and portfolio optimization. Additionally, she has held significant leadership roles at renowned companies such as Celgene, Merck, and Schering Plough.

Her extensive experience is complemented by her role as an independent consultant for biotech firms and foundations, as well as her volunteer work for Drew University's RISE program. Over her illustrious career, Dr. Lachowicz has co-authored more than 80 scientific publications, contributing valuable insights to the scientific community.

According to Avak Kahvejian, Ph.D., Founding CEO of Etiome and General Partner at Flagship Pioneering, “Jean is a proven R&D leader with a distinguished track record of translating discovery research into impactful clinical programs across diverse disease areas and modalities.” He adds that her strategic mindset and scientific leadership will play a crucial role in harnessing the potential of Etiome’s platform to redefine the treatment of diseases.

Dr. Lachowicz expressed her enthusiasm for joining Etiome at this pivotal moment, stating, “Etiome's mission to change our understanding of disease progression so we can intervene earlier is urgent and deeply compelling. I look forward to working with this talented team to transform how preemptive medicines are discovered, developed, and delivered.”

Etiome is at the forefront of transforming disease management through its groundbreaking Temporal Biodynamics™ platform. This platform is a sophisticated end-to-end technology designed to characterize diseases with increased resolution over time. Such advancements promise to accelerate the development of preemptive medicines that lead to better health outcomes for patients.

By revealing the dynamic molecular frameworks that define each stage of disease evolution, the Temporal Biodynamics™ platform enables the discovery of temporally informed therapeutic targets and biomarkers. These insights are instrumental in the development of Biostaged Medicines that have the potential to halt or even reverse disease progression before it becomes debilitating and irreversible.

Founded by Flagship Pioneering in 2021, Etiome is committed to redefining how diseases are detected and treated. As the company builds its pipeline of innovative solutions, it aims to create a healthier future for patients facing chronic and progressive diseases. With the addition of Jean Lachowicz to the leadership team, Etiome is well-positioned to make significant advancements in the field of preemptive medicine.

For more details about Etiome and its transformative initiatives, visit www.etiome.bio or follow them on LinkedIn and X.